Assessment of thrombotic risk during long-term treatment of immune thrombocytopenia with fostamatinib

BACKGROUND: Patients with immune thrombocytopenia (ITP) are at risk of bleeding and, paradoxically, thromboembolic events (TEEs), irrespective of thrombocytopenia. The risk of thrombosis is increased by advanced age, obesity, and prothrombotic comorbidities: cancer, hyperlipidemia, diabetes, hyperte...

Descripción completa

Detalles Bibliográficos
Autores principales: Cooper, Nichola, Altomare, Ivy, Thomas, Mark R., Nicolson, Phillip L. R., Watson, Steve P., Markovtsov, Vadim, Todd, Leslie K., Masuda, Esteban, Bussel, James B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8111531/
https://www.ncbi.nlm.nih.gov/pubmed/33995988
http://dx.doi.org/10.1177/20406207211010875

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8111531/
https://www.ncbi.nlm.nih.gov/pubmed/33995988
http://dx.doi.org/10.1177/20406207211010875

Ejemplares similares